Liposomal amphotericin B and leishmaniasis: dose and response
Shyam Sundar1, Jaya Chakravarty
1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.
Abstract:
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
More Related Videos
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
10:01Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites
Published on: March 16, 2018
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Antifungal Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion
Cryptococcal Meningitis
